Status
Completed
Phase
Phase 2
Enrollment
211
Locations
0
Results
Posted
Publications
0
Study summary
The purpose of this study is to evaluate the long-term safety and tolerability of etravirine, administered as part of an individually optimized antiretroviral therapy (ART), in human immunodeficiency virus Type 1 (HIV-1) infected participants.
This is a Phase II, open-label (all people know the identity of the intervention), roll-over study (participants may go ahead and participate in another clinical study). Participants who were randomized (study medication is assigned by chance) to a etravirine (ETR) treatment arm in Phase II TMC125 feeder studies (TMC125-C203, TMC125-C209, TMC125-C223 and TMC125-C211), were treated for at least 48 weeks with etravirine, and who will derive continued benefit from etravirine therapy, as judged by the investigator, will be enrolled in this study. The final visit of the sponsor-selected Phase II ETR study will be the first (baseline) visit of this study. Approximately 300 participants will be enrolled in this study who will receive 800 mg twice daily of etravirine (formulation TF035) until the formulation 200 mg twice daily (formulation F060) is available. Once this formulation becomes available all the participants will be switched to receive F060 which will be given in combination with an investigator-selected, optimized underlying therapy (nucleotide reverse transcriptase \[NRTIs\] and/or allowed protease inhibitors and/or enfuvirtide). Participants will continue to receive ETR until they are no longer benefitted or this medication becomes commercially available. Safety evaluations will include assessment of adverse events, clinical laboratory tests, electrocardiogram, vital signs, and physical examination.
Interventions
DRUG
Participants will receive 800 mg of ETR (2 x 4 tablets of formulation TF035) twice daily and after the formulation switch they will receive 200 mg of ETR (2 x 2 tablets of formulation F060) twice daily until the participants benefitted from etravirine or it became comercially available.
DRUG
Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
DRUG
Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
DRUG
Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
Timeline
First posted
Aug 10, 2005
Study start
Jun 2005
Primary completion
Aug 2008
Study completion
Aug 2008
Results posted
Apr 9, 2013
Registry updated
Jun 20, 2013
Outcomes
Number of Participants With Adverse Events
Time frame · Up to 3 years
Number of participants who reported at least 1 of the adverse events.
Number of Participants Who Achieved Virologic Response (ie, Viral Load Less Than 50 Copies/mL) at Week 48
Time frame · Week 48
Number of participants who had viral load more than or equal to 50 copies/mL and less than 50 copies/mL at TMC125-C229 baseline and who achieved virologic response (ie, viral load less than 50 copies/mL) at Week 48. The last visit of the TMC125 feeder study (TMC125-C203 \[NCT00412646\], TMC125-C223 \[NCT00081978\], TMC125 C211 \[NCT00111280\] or TMC125-C209 feeder studies) was considered to be the TMC125-C229 baseline.
Number of Participants Who Achieved Virologic Response (ie, Viral Load Less Than 50 Copies/mL) at Week 96
Time frame · Week 96
Number of participants who had viral load more than or equal to 50 copies/mL and less than 50 copies/mL at TMC125-C229 baseline and who achieved virologic response (ie, viral load less than 50 copies/mL) at Week 96. The last visit of the TMC125 feeder study (TMC125-C203 \[NCT00412646\], TMC125-C223 \[NCT00081978\], TMC125 C211 \[NCT00111280\] or TMC125-C209 feeder studies) was considered to be the TMC125-C229 baseline.
Number of Participants Who Achieved Virologic Response (ie, Viral Load Less Than 50 Copies/mL; Less Than 400 Copies/mL; and Greater Than or Equal to 1 Log 10 Decrease From Baseline) at Week 96
Time frame · Week 96
Baseline considered for this outcome is the baseline in the respective TMC125-C229 feeder study (TMC125-C203 \[NCT00412646\], TMC125-C223 \[NCT00081978\], TMC125 C211 \[NCT00111280\] or TMC125-C209 feeder studies).
Number of Participants Who Achieved Virologic Response (ie, Viral Load Less Than 50 Copies/mL; Viral Load Less Than 400 Copies/mL; and Greater Than or Equal to 1 log10 Decrease From Baseline) at Week 192
Time frame · Week 192
Baseline considered for this outcome is the baseline in the respective TMC125-C229 feeder study (TMC125-C203 \[NCT00412646\], TMC125-C223 \[NCT00081978\], TMC125 C211 \[NCT00111280\] or TMC125-C209 feeder studies).
Median Change From TMC125-C229 Basline in Cluster of Differentiation 4 (CD4+) Cell Count at Week 48
Time frame · Week 48
The last visit of the TMC125 feeder study (TMC125-C203 \[NCT00412646\], TMC125-C223 \[NCT00081978\], TMC125 C211 \[NCT00111280\] or TMC125-C209 feeder studies) was considered to be the TMC125-C229 baseline.
Median Change From TMC125-C229 Baseline in Cluster of Differentiation 4 (CD4+) Cell Count at Week 96
Time frame · Week 96
The last visit of the TMC125 feeder study (TMC125-C203 \[NCT00412646\], TMC125-C223 \[NCT00081978\], TMC125 C211 \[NCT00111280\] or TMC125-C209 feeder studies) was considered to be the TMC125-C229 baseline.
Median Change in Cluster of Differentiation 4 (CD4+) Cell Count From Baseline in TMC125-C229 Feeder Study at Week 96
Time frame · Week 96
Baseline considered for this outcome is the baseline in the respective TMC125-C229 feeder study (TMC125-C203 \[NCT00412646\], TMC125-C223 \[NCT00081978\], TMC125 C211 \[NCT00111280\] or TMC125-C209 feeder studies).
Median Change in Cluster of Differentiation 4 (CD4+) Cell Count From Baseline in TMC125-C229 Feeder Study at Week 192
Time frame · Week 192
Baseline considered for this outcome is the baseline in the respective TMC125-C229 feeder study (TMC125-C203 \[NCT00412646\], TMC125-C223 \[NCT00081978\], TMC125 C211 \[NCT00111280\] or TMC125-C209 feeder studies).
Number of Participants With Emerging Mutation (Reverse Transcriptase Mutation)
Time frame · Baseline and Endpoint (ie, the last available time point during the treatment period)
Emerging mutations are the mutation which are not present at baseline (last visit of the TMC125 feeder study \[TMC125-C203 (NCT00412646), TMC125-C223 (NCT00081978), TMC125 C211 (NCT00111280) or TMC125-C209 feeder studies\]) and are present at endpoint (last available timepoint during treatment period for each individual participant).
Eligibility
Inclusion Criteria: * Participants who were previously randomized to an etravirine (ETR) treatment arm and have completed at least 48 weeks of treatment with ETR * Participants who will be able to comply with the protocol requirements * Participants general medical condition should not interfere with the assessments and the completion of the study Exclusion Criteria: * Use of disallowed concomitant therapy unless a prior exemption had been granted * Participant with any treatment-emergent condition or exacerbation of underlying condition during original Phase II study * Agrees to protocol-defined use of effective contraception * Participant with a grade 3 elevation of amylase and/or lipase except for isolated grade 3 increases of amylase with lipase in normal range and no history of pancreatitis * Participant with any grade 4 toxicity according to the Division of Acquired Immunodeficiency Syndrome (DAIDS) grading table; with the exception of grade 4 elevations of triglycerides or glucose asymptomatic or under non-fasting conditions; grade 4 elevation of glucose in participants with pre-existing diabetes * Participants with clinical or laboratory evidence of significantly decreased hepatic function or decompensation, irrespective of liver enzyme levels (International Normalized Ratio \[INR\] more than 1.5 or albumin less than 30g/l or bilirubin more than 2.5 x upper limit of normal)
Study locations
No country data reported. Showing up to 24 locations stored in the fast local snapshot.
No study locations reported.
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
French National Agency for Research on AIDS and Viral Hepatitis · HIV Infections · AIDS
Phase 3
Completed
195
2026-04
French National Agency for Research on AIDS and Viral Hepatitis · HIV Infections
Phase 3
Completed
170
2026-04
ANRS, Emerging Infectious Diseases · HIV Infection · Liver Failure
Phase 1 / Phase 2
Completed
14
2026-04
French National Agency for Research on AIDS and Viral Hepatitis · Leukoencephalopathy, Progressive Multifocal · HIV Infections
Phase 2
Completed
30
2026-04
University Hospital, Tours · HIV
Phase 3
Completed
224
2025-12
Gilead Sciences · HIV-1-infection
Phase 2 / Phase 3
Active, not recruiting
689
2025-10
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · HIV
Early Phase 1
Completed
11
2021-11
National Institute of Allergy and Infectious Diseases (NIAID) · HIV Infections
Phase 3
Completed
517
2021-11
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.